ASX - By Stock
|
SMN |
Re:
Airline industry
|
|
mool
|
34 |
12K |
9 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
34
|
12K
|
9
|
|
ASX - By Stock
|
AX1 |
Re:
Ann: Trading Update
|
|
mool
|
26 |
11K |
3 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
26
|
11K
|
3
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Capital Raising
|
|
mool
|
149 |
43K |
0 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
149
|
43K
|
0
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Pause in Trading
|
|
mool
|
29 |
8.1K |
15 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
29
|
8.1K
|
15
|
|
ASX - By Stock
|
SMN |
Re:
SMN Valuation
|
|
mool
|
212 |
67K |
5 |
04/01/22 |
04/01/22 |
ASX - By Stock
|
212
|
67K
|
5
|
|
ASX - By Stock
|
SMN |
Re:
SMN Valuation
|
|
mool
|
212 |
67K |
1 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
212
|
67K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Capital Rasing Deferred
|
|
mool
|
22 |
6.1K |
1 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
22
|
6.1K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Capital Rasing Deferred
|
|
mool
|
22 |
6.1K |
5 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
22
|
6.1K
|
5
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Capital Rasing Deferred
|
|
mool
|
22 |
6.1K |
7 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
22
|
6.1K
|
7
|
|
ASX - By Stock
|
AX1 |
Re:
Ann: Reebok Distribution Agreement
|
|
mool
|
5 |
1.4K |
0 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
5
|
1.4K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
mool
|
1.0K |
278K |
4 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
278K
|
4
|
|
Charts
|
SMN |
Re:
discussion on cap raise with and without FAA approval
|
|
mool
|
3 |
1.2K |
10 |
12/11/21 |
12/11/21 |
Charts
|
3
|
1.2K
|
10
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Company Update & Capital Raising
|
|
mool
|
127 |
41K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
127
|
41K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Proposed issue of securities - SMN
|
|
mool
|
2 |
1.0K |
6 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
2
|
1.0K
|
6
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Notice of Requisition for EGM
|
|
mool
|
294 |
82K |
5 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
294
|
82K
|
5
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Extension to voluntary suspension
|
|
mool
|
50 |
15K |
2 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
50
|
15K
|
2
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Extension to voluntary suspension
|
|
mool
|
37 |
11K |
1 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
37
|
11K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Extension to voluntary suspension
|
|
mool
|
37 |
11K |
4 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
37
|
11K
|
4
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
157 |
41K |
0 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
157
|
41K
|
0
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
157 |
41K |
1 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
157
|
41K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
157 |
41K |
1 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
157
|
41K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
157 |
41K |
2 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
157
|
41K
|
2
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
157 |
41K |
2 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
157
|
41K
|
2
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Trading Halt
|
|
mool
|
36 |
11K |
6 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
36
|
11K
|
6
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Notification of cessation of securities - SMN
|
|
mool
|
10 |
3.4K |
6 |
06/08/21 |
06/08/21 |
ASX - By Stock
|
10
|
3.4K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
mool
|
281 |
77K |
0 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
281
|
77K
|
0
|
|
ASX - By Stock
|
FLC |
Re:
Ann: Fluence Business Update for Q2 2021
|
|
mool
|
34 |
9.0K |
4 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
34
|
9.0K
|
4
|
|
ASX - By Stock
|
AX1 |
Re:
Ann: HOKA ONE ONE Distribution Agreement
|
|
mool
|
25 |
6.9K |
2 |
29/03/21 |
29/03/21 |
ASX - By Stock
|
25
|
6.9K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
mool
|
5.4K |
2.6M |
1 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
5.4K
|
2.6M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
mool
|
763 |
324K |
1 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
324K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
mool
|
1.0K |
418K |
10 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
418K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
mool
|
1.0K |
418K |
30 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
418K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
0 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
mool
|
1.0K |
418K |
27 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
418K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
2 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
1 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
6 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
0 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
mool
|
125 |
55K |
2 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
55K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
mool
|
416 |
132K |
0 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
416
|
132K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
mool
|
572 |
251K |
8 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
251K
|
8
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Further Material Progress to Pivotal STC
|
|
mool
|
40 |
11K |
10 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
40
|
11K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
mool
|
17K |
6.7M |
12 |
12/11/20 |
12/11/20 |
ASX - By Stock
|
17K
|
6.7M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
mool
|
392 |
158K |
20 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
158K
|
20
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
mool
|
28 |
7.2K |
16 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
28
|
7.2K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
mool
|
635 |
277K |
1 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
277K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
mool
|
13K |
5.0M |
4 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
FLC |
Re:
Ann: Fluence secures $20M Finance Facility
|
|
mool
|
25 |
9.7K |
6 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
25
|
9.7K
|
6
|
|
ASX - By Stock
|
FLC |
Re:
Ann: Fluence secures $20M Finance Facility
|
|
mool
|
25 |
9.7K |
3 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
25
|
9.7K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
mool
|
13K |
5.0M |
6 |
19/09/20 |
19/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
6
|
|